Baxalta: A Rare Undervalued Biopharmaceutical Company

Baxalta (BXLT) was created on July 1st 2015 when Baxter (BAX) spun-off its biopharmaceutical division. Baxalta may be new, but it is no start-up company.  Baxalta has estimated annual revenues of around $6 billion, and 16,000 employees. Around 50% of Baxalta’s sales come from the United States, with the other 50% from international markets. The … Read more

CTI BioPharma (CTIC) Stock Climbs On Positive Data

CTI Biopharma (NASDAQ: CTIC) | Baxter International’s Bioscience Business (NYSE: BAX) The ASCO 2015 meeting is proving to be a big hit in the world of biotech; and CTIC is making waves. CTI Biopharma and Baxter International’s Bioscience announced data from a Phase 3 registration-directed trial that examined pacritinib for the treatment of myleofibrosis. Today, … Read more